Global Overactive Bladder Treatment Drug Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Overactive Bladder Treatment Drug Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Anticholinergics
  • 1.4.3 Solifenacin
  • 1.4.4 Oxybutynin
  • 1.4.5 Darifenacin
  • 1.4.6 Fesoterodine
  • 1.4.7 Tolterodine
  • 1.4.8 Trospium
  • 1.4.9 Others
• 1.5 Market by Application
  • 1.5.1 Global Overactive Bladder Treatment Drug Market Share by Application (2014-2025)
  • 1.5.2 Idiopathic Bladder Overactivity
  • 1.5.3 Neurogenic Bladder Overactivity
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Overactive Bladder Treatment Drug Market Size
• 2.2 Overactive Bladder Treatment Drug Growth Trends by Regions
  • 2.2.1 Overactive Bladder Treatment Drug Market Size by Regions (2014-2025)
  • 2.2.2 Overactive Bladder Treatment Drug Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Overactive Bladder Treatment Drug Market Size by Manufacturers
  • 3.1.1 Global Overactive Bladder Treatment Drug Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Overactive Bladder Treatment Drug Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Overactive Bladder Treatment Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Overactive Bladder Treatment Drug Key Players Head office and Area Served
• 3.3 Key Players Overactive Bladder Treatment Drug Product/Solution/Service
• 3.4 Date of Enter into Overactive Bladder Treatment Drug Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Overactive Bladder Treatment Drug Market Size by Type (2014-2019)
• 4.2 Global Overactive Bladder Treatment Drug Market Size by Application (2014-2019)

5 United States

• 5.1 United States Overactive Bladder Treatment Drug Market Size (2014-2019)
• 5.2 Overactive Bladder Treatment Drug Key Players in United States
• 5.3 United States Overactive Bladder Treatment Drug Market Size by Type
• 5.4 United States Overactive Bladder Treatment Drug Market Size by Application

6 Europe

• 6.1 Europe Overactive Bladder Treatment Drug Market Size (2014-2019)
• 6.2 Overactive Bladder Treatment Drug Key Players in Europe
• 6.3 Europe Overactive Bladder Treatment Drug Market Size by Type
• 6.4 Europe Overactive Bladder Treatment Drug Market Size by Application

7 China

• 7.1 China Overactive Bladder Treatment Drug Market Size (2014-2019)
• 7.2 Overactive Bladder Treatment Drug Key Players in China
• 7.3 China Overactive Bladder Treatment Drug Market Size by Type
• 7.4 China Overactive Bladder Treatment Drug Market Size by Application

8 Japan

• 8.1 Japan Overactive Bladder Treatment Drug Market Size (2014-2019)
• 8.2 Overactive Bladder Treatment Drug Key Players in Japan
• 8.3 Japan Overactive Bladder Treatment Drug Market Size by Type
• 8.4 Japan Overactive Bladder Treatment Drug Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Overactive Bladder Treatment Drug Market Size (2014-2019)
• 9.2 Overactive Bladder Treatment Drug Key Players in Southeast Asia
• 9.3 Southeast Asia Overactive Bladder Treatment Drug Market Size by Type
• 9.4 Southeast Asia Overactive Bladder Treatment Drug Market Size by Application

10 India

• 10.1 India Overactive Bladder Treatment Drug Market Size (2014-2019)
• 10.2 Overactive Bladder Treatment Drug Key Players in India
• 10.3 India Overactive Bladder Treatment Drug Market Size by Type
• 10.4 India Overactive Bladder Treatment Drug Market Size by Application

11 Central & South America

• 11.1 Central & South America Overactive Bladder Treatment Drug Market Size (2014-2019)
• 11.2 Overactive Bladder Treatment Drug Key Players in Central & South America
• 11.3 Central & South America Overactive Bladder Treatment Drug Market Size by Type
• 11.4 Central & South America Overactive Bladder Treatment Drug Market Size by Application

12 International Players Profiles

• 12.1 Astellas Pharma, Inc. (Japan)
  • 12.1.1 Astellas Pharma, Inc. (Japan) Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Overactive Bladder Treatment Drug Introduction
  • 12.1.4 Astellas Pharma, Inc. (Japan) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
  • 12.1.5 Astellas Pharma, Inc. (Japan) Recent Development
• 12.2 Pfizer, Inc. (U.S.)
  • 12.2.1 Pfizer, Inc. (U.S.) Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Overactive Bladder Treatment Drug Introduction
  • 12.2.4 Pfizer, Inc. (U.S.) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
  • 12.2.5 Pfizer, Inc. (U.S.) Recent Development
• 12.3 Teva Pharmaceutical Industries Limited (Israel)
  • 12.3.1 Teva Pharmaceutical Industries Limited (Israel) Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Overactive Bladder Treatment Drug Introduction
  • 12.3.4 Teva Pharmaceutical Industries Limited (Israel) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
  • 12.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Development
• 12.4 Allergan, Plc (Ireland)
  • 12.4.1 Allergan, Plc (Ireland) Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Overactive Bladder Treatment Drug Introduction
  • 12.4.4 Allergan, Plc (Ireland) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
  • 12.4.5 Allergan, Plc (Ireland) Recent Development
• 12.5 Medtronic plc (Ireland)
  • 12.5.1 Medtronic plc (Ireland) Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Overactive Bladder Treatment Drug Introduction
  • 12.5.4 Medtronic plc (Ireland) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
  • 12.5.5 Medtronic plc (Ireland) Recent Development
• 12.6 Mylan N.V. (U.S.)
  • 12.6.1 Mylan N.V. (U.S.) Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Overactive Bladder Treatment Drug Introduction
  • 12.6.4 Mylan N.V. (U.S.) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
  • 12.6.5 Mylan N.V. (U.S.) Recent Development
• 12.7 Endo International plc (Ireland)
  • 12.7.1 Endo International plc (Ireland) Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Overactive Bladder Treatment Drug Introduction
  • 12.7.4 Endo International plc (Ireland) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
  • 12.7.5 Endo International plc (Ireland) Recent Development
• 12.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • 12.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Overactive Bladder Treatment Drug Introduction
  • 12.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
  • 12.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Development
• 12.9 Sanofi (France)
  • 12.9.1 Sanofi (France) Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Overactive Bladder Treatment Drug Introduction
  • 12.9.4 Sanofi (France) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
  • 12.9.5 Sanofi (France) Recent Development
• 12.10 Apotex, Inc. (Canada)
  • 12.10.1 Apotex, Inc. (Canada) Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Overactive Bladder Treatment Drug Introduction
  • 12.10.4 Apotex, Inc. (Canada) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
  • 12.10.5 Apotex, Inc. (Canada) Recent Development
• 12.11 Cogentix Medical, Inc. (U.S.)
• 12.12 Aurobindo Pharma Limited (India)

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer